Exelixis (EXEL) Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline

Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline

Exelixis has exclusive license to panel of monoclonal antibodies against an undisclosed oncology target for biologics applications, leveraging WuXi Biologics integrated technology platforms

In addition to a modest upfront payment, WuXi Biologics is eligible for potential milestones and royalties on net sales of potential products

ALAMEDA, Calif. & SHANGHAI--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) and WuXi Biologics (WuXi Bio) (2269.HK) today announced the companies have entered into an exclusive license agreement to support the continued expansion of Exelixis oncology biologics pipeline. The agreement is... More